Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1998 1
1999 1
2000 1
2003 2
2004 3
2005 2
2006 5
2007 2
2009 3
2010 3
2011 6
2012 4
2013 5
2014 9
2015 9
2016 8
2017 2
2018 8
2019 9
2020 6
2021 18
2022 16
2023 17
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.
Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators. Kim YH, et al. Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Lancet Oncol. 2018. PMID: 30100375 Free article. Clinical Trial.
Mechanisms of resistance to mogamulizumab.
Querfeld C. Querfeld C. Blood. 2022 Jun 30;139(26):3674-3676. doi: 10.1182/blood.2022016594. Blood. 2022. PMID: 35771561 Free article. No abstract available.
CD30-Positive Lymphoproliferative Disorders.
Nikolaenko L, Zain J, Rosen ST, Querfeld C. Nikolaenko L, et al. Among authors: querfeld c. Cancer Treat Res. 2019;176:249-268. doi: 10.1007/978-3-319-99716-2_12. Cancer Treat Res. 2019. PMID: 30596222
Pembrolizumab-associated sarcoidosis.
Cotliar J, Querfeld C, Boswell WJ, Raja N, Raz D, Chen R. Cotliar J, et al. Among authors: querfeld c. JAAD Case Rep. 2016 Jul 27;2(4):290-3. doi: 10.1016/j.jdcr.2016.06.004. eCollection 2016 Jul. JAAD Case Rep. 2016. PMID: 27504482 Free PMC article. No abstract available.
Targeting microRNA in hematologic malignancies.
Han Z, Rosen ST, Querfeld C. Han Z, et al. Among authors: querfeld c. Curr Opin Oncol. 2020 Sep;32(5):535-544. doi: 10.1097/CCO.0000000000000657. Curr Opin Oncol. 2020. PMID: 32657797 Free PMC article. Review.
Emerging drugs for the treatment of cutaneous T-cell lymphoma.
Cheng M, Zain J, Rosen ST, Querfeld C. Cheng M, et al. Among authors: querfeld c. Expert Opin Emerg Drugs. 2022 Mar;27(1):45-54. doi: 10.1080/14728214.2022.2049233. Epub 2022 Mar 8. Expert Opin Emerg Drugs. 2022. PMID: 35235473 Free PMC article. Review.
Mechanism of action of chlormethine gel in mycosis fungoides.
Guenova E, Ortiz-Romero PL, Poligone B, Querfeld C. Guenova E, et al. Among authors: querfeld c. J Eur Acad Dermatol Venereol. 2023 Sep;37(9):1739-1748. doi: 10.1111/jdv.19237. Epub 2023 Jul 1. J Eur Acad Dermatol Venereol. 2023. PMID: 37262305 Review.
128 results